Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine
Oncology
Dr. Lee S. Schwartzberg, MD
|
|
Give Review
Lee S. Schwartzberg, MD works in the field of Oncology. He attended New York Medical College. He has 5 awards "America's Top Doctors", "Memphis Magazine: Top Doctors", "America's Top Doctors for Cancer", "Physician Practice Connections Recognition Program" and "Top MD". Dr. Lee S. Schwartzberg has written publications. He has 53 publications published with PubMed. The lastest publication is: 'Prevalence And Reasons For Nonadherence To Aromatase Inhibitors In An Outpatient Oncology Clinic.'
Publications
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast Cancer previously treated with an anthracycline, a taxane, and capec...
- Prevalence And Reasons For Nonadherence To Aromatase Inhibitors In An Outpatient Oncology Clinic.
- Evaluation Of Resource Utilizaton For Chemotherapy Induced Nausea And Vomiting (Cinv) In Patients Treated With Anthracycline+Cyclophosphamide (Ac) For Solid Cancers Wi...
- Lipegfilgrastim For Reduction Of Chemotherapy-Induced Neutropenia Related Events: A Meta-Analysis.
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in ...
- Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracyclin...
- Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal Cancer.
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer.
- Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patien...
- Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.
- Open-label, single-arm, phase II study of enzastaurin in patients with follicular Lymphoma.
- A randomized Phase 3 study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced ...
- Early treatment discontinuation and switching in first-line metastatic breast Cancer: the role of patient-reported symptom burden.
- Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin's Lymphoma receiving CHOP-based chemotherapy.
- Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung Cancer after platinum-based therapy: a phase 3, open-label, randomise...
- Pooled Analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomi...
- Willingness to pay to prevent chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal Cancer.
- TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal Cancer: A randomized phase 1b/2 trial.
- Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favo...
- Prospective Observational Comparison of Clinical Outcomes Between African-American and Caucasian Patients Receiving Second-Line Treatment With Pemetrexed for Advanced ...
- Oncology Comparative Effectiveness Research: A Multistakeholder Perspective on Principles for ConDuct and Reporting.
- Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab.
- Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal ca...
- The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic Cancer in the community setting.
- Relationship between incidence of fracture and health-related quality-of-life in metastatic breast Cancer patients with bone metastases.
- Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer.
- Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast Cancer patients.
- Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion.
- Payer and provider collaborations that improve quality outcomes in oncology.
- Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: R...
- Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast Cancer.
- Second- and third-line treatment of patients with non-small-cell lung Cancer with erlotinib in the community setting: retrospective study of patient healthcare utiliza...
- Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast Cancer that progressed on first- or second-line trastuzumab-containing regimens.
- A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carbo...
- The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with Cancer.
- Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast Cancer.
- Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-Cell and mantle Cell non-Hodgkin's lymphoma.
- Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community Setting.
- Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
- Patient-specific vaccines derived from autologous tumor Cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastat...
- Chemotherapy-induced nausea and vomiting: clinician and patient perspectives.
- A prospective investigation of chemotherapy-induced neutropenia and quality of life.
- Erythropoietic therapy: who, how, and when?
- Neutropenia: etiology and pathogenesis.
- Sex differences in patients who have Cancer with mild anemia: symptom burden and quality of life.
- First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast Cancer: a multicenter, double-blind, placebo-controlled phase III ...
- Managing the toxicity of hematopoietic stem Cell transplant.
- A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced Anemia in patients with breast, lung, or gyn...
- Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon Cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
- High-Dose Chemotherapy with Peripheral Blood Stem Cell Support for Operable Locally Advanced Noninflammatory Carcinoma of the Breast.
- A review of rapid-onset opioids for breakthrough pain in patients with Cancer.
Schools
New York Medical College
North Shore University Hospital
Sloan Kettering Canc Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Memphis Magazine: Top Doctors
- America's Top Doctors for Cancer
- Physician Practice Connections Recognition Program
- Top MD
Education
-
Memorial Sloan-Kettering Cancer Center -
North Shore-Long Island Jewish Health System -
New York Medical College
Hospital
-
University of Tennessee Medical Center
Drug Facts
| NPI NUMBER | 1306878228 | |
| NPPES Provider LastName | SCHWARTZBERG | |
| NPPES Provider FirstName | LEE | |
| NPPES Provider ZIPCode | 381202146 | |
| NPPES Provider State | TN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1908.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 118.0 | |
| Percent Opioid Claims | 6.18 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306878228 |
| Last Name Of The Provider | SCHWARTZBERG |
| First Name Of The Provider | LEE |
| View All |
Similar Doctors
|
Dr. Marion Dugdale, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Suhail Obaji, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Albert E. Weeks, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alva Weir, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kurt W. Tauer, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sylvia S. Richey, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Roy C. Page, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Drew S. Dill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian P. Sorrentino, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Darlene K. Cash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mansoor U. Haq, MD |
|
|
Dr. William H. West, MD |
|
|
Dr. Jason C. Chandler, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Benton Wheeler, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bradley G. Somer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ari M. Vanderwalde, MD
This Doctor is OpenDoctor Recommended.
|